These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 23624782)
1. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782 [TBL] [Abstract][Full Text] [Related]
2. TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women. Zając A; Smolarz B; Stachowiak G; Wilczyński JR Med Oncol; 2014 Nov; 31(11):286. PubMed ID: 25316267 [TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S Hum Cell; 2009 Nov; 22(4):101-6. PubMed ID: 19874399 [TBL] [Abstract][Full Text] [Related]
4. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study. Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146 [TBL] [Abstract][Full Text] [Related]
5. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596 [TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. Wan Y; Wu W; Yin Z; Guan P; Zhou B BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694 [TBL] [Abstract][Full Text] [Related]
7. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis. Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912 [TBL] [Abstract][Full Text] [Related]
8. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578 [TBL] [Abstract][Full Text] [Related]
9. Impact of Wujcicka W; Zając A; Stachowiak G In Vivo; 2019; 33(3):917-924. PubMed ID: 31028217 [TBL] [Abstract][Full Text] [Related]
10. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer. Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369 [TBL] [Abstract][Full Text] [Related]
11. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539 [TBL] [Abstract][Full Text] [Related]
12. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area. Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800 [TBL] [Abstract][Full Text] [Related]
13. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Walsh CS; Miller CW; Karlan BY; Koeffler HP Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590 [TBL] [Abstract][Full Text] [Related]
14. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639 [TBL] [Abstract][Full Text] [Related]
15. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199 [TBL] [Abstract][Full Text] [Related]
16. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study. Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836 [TBL] [Abstract][Full Text] [Related]
17. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma. Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739 [TBL] [Abstract][Full Text] [Related]
18. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. Capasso M; Ayala F; Avvisati RA; Russo R; Gambale A; Mozzillo N; Ascierto PA; Iolascon A J Hum Genet; 2010 Aug; 55(8):518-24. PubMed ID: 20535124 [TBL] [Abstract][Full Text] [Related]
19. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578 [TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]